{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:16Z","timestamp":1794047476143,"version":"4.8.0"},"reference-count":32,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"1","license":[{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Multiple myeloma (MM) is a plasma cell malignancy that is considered incurable despite the recent therapeutic advances. Effective targeted therapies are, therefore, needed. Our previous studies proved that inhibiting CDK7 impairs the cell cycle and metabolic programs by disrupting E2F1 and MYC transcriptional activities, making it an appealing therapeutic target for MM. Given that CDK7 and BRD4 operate in two distinct regulatory axes in MM, we hypothesized that targeting these two complementary pathways simultaneously would lead to a deeper and more durable response. Indeed, combination therapy had superior activity against MM cell growth and viability, and induced apoptosis to a greater extent than did single-agent therapy in both cell lines and patients\u2019 cells. This synergistic activity was also observed in Waldenstr\u00f6m macroglobulinemia (WM) cells and with other inhibitors of E2F1 activity. Dual inhibition effectively impaired the MYC and E2F transcriptional programs and MM tumor growth and progression in xenograft animal models, providing evidence for the potential of combination therapy as a therapeutic strategy in MM and WM.<\/jats:p>","DOI":"10.3324\/haematol.2024.285491","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T02:56:53Z","timestamp":1721876213000},"page":"153-162","source":"Crossref","is-referenced-by-count":0,"title":["Unlocking the therapeutic potential of selective CDK7 and BRD4 inhibition against multiple myeloma cell growth"],"prefix":"10.3324","volume":"110","author":[{"given":"Yao","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhui","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica Fong","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandraditya","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"JoyWeiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Fulciniti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,7,25]]},"reference":[{"key":"71022","doi-asserted-by":"crossref","unstructured":"Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005; 106(1):296-303.","DOI":"10.1182\/blood-2005-01-0034"},{"key":"71023","doi-asserted-by":"crossref","unstructured":"Fulciniti M, Martinez-Lopez J, Senapedis W. Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. Blood. 2017; 129(16):2233-2245.","DOI":"10.1182\/blood-2016-06-724831"},{"key":"71024","doi-asserted-by":"crossref","unstructured":"Li N, Lopez MA, Linares M. Dual PAK4-NAMPT inhibition impacts growth and survival, and increases sensitivity to DNA-damaging agents in Waldenstrom macroglobulinemia. Clin Cancer Res. 2019; 25(1):369-377.","DOI":"10.1158\/1078-0432.CCR-18-1776"},{"key":"71025","doi-asserted-by":"crossref","unstructured":"Ng YLD, Ramberger E, Bohl SR. Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma. Nat Commun. 2022; 13(1):1009.","DOI":"10.1038\/s41467-022-28515-1"},{"key":"71026","doi-asserted-by":"crossref","unstructured":"de Matos Simoes R, Shirasaki R, Downey-Kopyscinski SL. Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias. Nat Cancer. 2023; 4(5):754-773.","DOI":"10.1038\/s43018-023-00550-x"},{"key":"71027","doi-asserted-by":"crossref","unstructured":"Filippakopoulos P, Picaud S, Mangos M. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell. 2012; 149(1):214-231.","DOI":"10.1016\/j.cell.2012.02.013"},{"key":"71028","doi-asserted-by":"crossref","unstructured":"Fujisawa T, Filippakopoulos P. Functions of bromodomaincontaining proteins and their roles in homeostasis and cancer. Nat Rev Mol Cell Biol. 2017; 18(4):246-262.","DOI":"10.1038\/nrm.2016.143"},{"key":"71029","doi-asserted-by":"crossref","unstructured":"Filippakopoulos P, Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov. 2014; 13(5):337-356.","DOI":"10.1038\/nrd4286"},{"key":"71030","doi-asserted-by":"crossref","unstructured":"Delmore JE, Issa GC, Lemieux ME. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011; 146(6):904-917.","DOI":"10.1016\/j.cell.2011.08.017"},{"key":"71031","doi-asserted-by":"crossref","unstructured":"Chaidos A, Caputo V, Gouvedenou K. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood. 2014; 123(5):697-705.","DOI":"10.1182\/blood-2013-01-478420"},{"key":"71032","doi-asserted-by":"crossref","unstructured":"Stubbs MC, Burn TC, Sparks R. The novel bromodomain and extraterminal domain inhibitor INCB054329 induces vulnerabilities in myeloma cells that inform rational combination strategies. Clin Cancer Res. 2019; 25(1):300-311.","DOI":"10.1158\/1078-0432.CCR-18-0098"},{"key":"71033","doi-asserted-by":"crossref","unstructured":"Zhang X, Lee HC, Shirazi F. Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma. Leukemia. 2018; 32(10):2224-2239.","DOI":"10.1038\/s41375-018-0044-x"},{"key":"71034","doi-asserted-by":"crossref","unstructured":"Amorim S, Stathis A, Gleeson M. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. Lancet Haematol. 2016; 3(4):e196-204.","DOI":"10.1016\/S2352-3026(16)00021-1"},{"key":"71035","doi-asserted-by":"crossref","unstructured":"Sun Y, Han J, Wang Z, Li X, Sun Y, Hu Z. Safety and efficacy of bromodomain and extra-terminal inhibitors for the treatment of hematological malignancies and solid tumors: a systematic study of clinical trials. Front Pharmacol. 2020; 11:621093.","DOI":"10.3389\/fphar.2020.621093"},{"key":"71036","doi-asserted-by":"crossref","unstructured":"Stathis A, Bertoni F. BET proteins as targets for anticancer treatment. Cancer Discov. 2018; 8(1):24-36.","DOI":"10.1158\/2159-8290.CD-17-0605"},{"key":"71037","doi-asserted-by":"crossref","unstructured":"Fulciniti M, Lin CY, Samur MK. Non-overlapping control of transcriptome by promoter- and super-enhancer-associated dependencies in multiple myeloma. Cell Rep. 2018; 25(13):3693-3705.e6.","DOI":"10.1016\/j.celrep.2018.12.016"},{"key":"71038","doi-asserted-by":"crossref","unstructured":"Yao Y, Ng JF, Park WD. CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma. Blood. 2023; 141(23):2841-2852.","DOI":"10.1182\/blood.2022018885"},{"key":"71039","doi-asserted-by":"crossref","unstructured":"Wang Y, Manokaran C, Wu S, Roberts TM. The Mediator captures CDK7, an attractive transcriptional target in cancer. Cancer Cell. 2021; 39(9):1184-1186.","DOI":"10.1016\/j.ccell.2021.07.021"},{"key":"71040","doi-asserted-by":"crossref","unstructured":"Olson CM, Liang Y, Leggett A. Development of a selective CDK7 covalent inhibitor reveals predominant cell-cycle phenotype. Cell Chem Biol. 2019; 26(6):792-803.e10.","DOI":"10.1016\/j.chembiol.2019.02.012"},{"key":"71041","doi-asserted-by":"crossref","unstructured":"Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood. 1993; 82(12):3712-3720.","DOI":"10.1182\/blood.V82.12.3712.3712"},{"key":"71042","doi-asserted-by":"crossref","unstructured":"Hideshima T, Mitsiades C, Ikeda H. A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. Blood. 2010; 115(18):3772-3775.","DOI":"10.1182\/blood-2010-02-270082"},{"key":"71043","doi-asserted-by":"crossref","unstructured":"Feng M, Xu H, Zhou W, Pan Y. The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma. J Exp Clin Cancer Res. 2023; 42(1):44.","DOI":"10.1186\/s13046-023-02615-2"},{"key":"71044","doi-asserted-by":"crossref","unstructured":"Gao Y, Volegova M, Nasholm N. Synergistic anti-tumor effect of combining selective CDK7 and BRD4 inhibition in neuroblastoma. Front Oncol. 2022; 11:773186.","DOI":"10.3389\/fonc.2021.773186"},{"key":"71045","doi-asserted-by":"crossref","unstructured":"Zhang W, Ge H, Jiang Y. Combinational therapeutic targeting of BRD4 and CDK7 synergistically induces anticancer effects in head and neck squamous cell carcinoma. Cancer Lett. 2020; 469:510-523.","DOI":"10.1016\/j.canlet.2019.11.027"},{"key":"71046","doi-asserted-by":"crossref","unstructured":"Choudhury SR, Ashby C, Tytarenko R. The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma. J Hematol Oncol. 2020; 13(1):108.","DOI":"10.1186\/s13045-020-00933-y"},{"key":"71047","doi-asserted-by":"crossref","unstructured":"Cardona-Benavides IJ, de Ramon C, Gutierrez NC. Genetic abnormalities in multiple myeloma: prognostic and therapeutic implications. Cells. 2021; 10(2):336.","DOI":"10.3390\/cells10020336"},{"key":"71048","doi-asserted-by":"crossref","unstructured":"Xie Z, Bi C, Chooi JY, Chan ZL, Mustafa N, Chng WJ. MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib. Leukemia. 2015; 29(12):2347-2354.","DOI":"10.1038\/leu.2015.169"},{"key":"71049","doi-asserted-by":"crossref","unstructured":"Tiedemann RE, Mao X, Shi CX. Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity. J Clin Invest. 2008; 118(5):1750-1764.","DOI":"10.1172\/JCI34149"},{"key":"71050","doi-asserted-by":"crossref","unstructured":"Jovanovic KK, Roche-Lestienne C, Ghobrial IM, Facon T, Quesnel B, Manier S. Targeting MYC in multiple myeloma. Leukemia. 2018; 32(6):1295-1306.","DOI":"10.1038\/s41375-018-0036-x"},{"key":"71051","doi-asserted-by":"crossref","unstructured":"Arora M, Moser J, Hoffman TE. Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity. Cell. 2023; 186(12):2628-2643.","DOI":"10.1016\/j.cell.2023.05.013"},{"key":"71052","doi-asserted-by":"crossref","unstructured":"Ge JY, Shu S, Kwon M. Acquired resistance to combined BET and CDK4\/6 inhibition in triple-negative breast cancer. Nat Commun. 2020; 11(1):2350.","DOI":"10.1038\/s41467-020-16170-3"},{"key":"71053","doi-asserted-by":"crossref","unstructured":"Ding D, Zheng R, Tian Y. Retinoblastoma protein as an intrinsic BRD4 inhibitor modulates small molecule BET inhibitor sensitivity in cancer. Nat Commun. 2022; 13(1):6311.","DOI":"10.1038\/s41467-022-34024-y"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285491\/77900","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285491\/77947","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11703\/77322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:06:58Z","timestamp":1794046018000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.285491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,25]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285491","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,25]]}}}